A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Lupin receives US FDA approval for generic Atrovent nasal spray, 0.06%: Our Bureau,Mumbai Tuesday, January 28, 2025, 17:30 Hrs [IST] Global pharma major Lupin Limited (Lupin) anno ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

“With the global nasal spray market projected to reach over $23 billion by 2029 ... CDMO offers a powerful network of companies across Europe, North America and India that provide comprehensive, ...